NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells.
| dc.contributor.author | Simma, Narasimhulu | |
| dc.contributor.author | Bose, Tanima | |
| dc.contributor.author | Kahlfuss, Sascha | |
| dc.contributor.author | Mankiewicz, Judith | |
| dc.contributor.author | Lowinus, Theresa | |
| dc.contributor.author | Lühder, Fred | |
| dc.contributor.author | Schüler, Thomas | |
| dc.contributor.author | Schraven, Burkhart | |
| dc.contributor.author | Heine, Martin | |
| dc.contributor.author | Bommhardt, Ursula | |
| dc.date.accessioned | 2015-11-04T12:50:47Z | en |
| dc.date.available | 2015-11-04T12:50:47Z | en |
| dc.date.issued | 2014 | en |
| dc.identifier.citation | NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. 2014, 12:75 Cell Commun. Signal | en |
| dc.identifier.issn | 1478-811X | en |
| dc.identifier.pmid | 25477292 | en |
| dc.identifier.doi | 10.1186/s12964-014-0075-5 | en |
| dc.identifier.uri | http://hdl.handle.net/10033/581714 | en |
| dc.description.abstract | B cells are important effectors and regulators of adaptive and innate immune responses, inflammation and autoimmunity, for instance in anti-NMDA-receptor (NMDAR) encephalitis. Thus, pharmacological modulation of B-cell function could be an effective regimen in therapeutic strategies. Since the non-competitive NMDAR antagonist memantine is clinically applied to treat advanced Alzheimer`s disease and ketamine is supposed to improve the course of resistant depression, it is important to know how these drugs affect B-cell function. | |
| dc.language.iso | en | en |
| dc.subject.mesh | Animals | en |
| dc.subject.mesh | Antigens, CD40 | en |
| dc.subject.mesh | Apoptosis | en |
| dc.subject.mesh | B-Lymphocytes | en |
| dc.subject.mesh | Cell Proliferation | en |
| dc.subject.mesh | Immunoglobulin G | en |
| dc.subject.mesh | Immunoglobulin M | en |
| dc.subject.mesh | Interferon-gamma | en |
| dc.subject.mesh | Interleukin-10 | en |
| dc.subject.mesh | Intermediate-Conductance Calcium-Activated Potassium Channels | en |
| dc.subject.mesh | Kv1.3 Potassium Channel | en |
| dc.subject.mesh | Lipopolysaccharides | en |
| dc.subject.mesh | Mice, Inbred C57BL | en |
| dc.subject.mesh | Mice, Transgenic | en |
| dc.subject.mesh | Piperidines | en |
| dc.subject.mesh | Receptors, Antigen, B-Cell | en |
| dc.subject.mesh | Receptors, N-Methyl-D-Aspartate | en |
| dc.subject.mesh | Toll-Like Receptor 4 | en |
| dc.title | NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. | en |
| dc.type | Article | en |
| dc.contributor.department | Helmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany. | en |
| dc.identifier.journal | Cell communication and signaling : CCS | en |
| refterms.dateFOA | 2018-06-13T03:45:56Z | |
| html.description.abstract | B cells are important effectors and regulators of adaptive and innate immune responses, inflammation and autoimmunity, for instance in anti-NMDA-receptor (NMDAR) encephalitis. Thus, pharmacological modulation of B-cell function could be an effective regimen in therapeutic strategies. Since the non-competitive NMDAR antagonist memantine is clinically applied to treat advanced Alzheimer`s disease and ketamine is supposed to improve the course of resistant depression, it is important to know how these drugs affect B-cell function. |
